Insight
Erman Akkus Summarizes 5-year Results of CheckMate 040

Erman Akkus Summarizes 5-year Results of CheckMate 040

Erman Akkus, Medical Oncology Fellow at Ankara University, shared a post on X:

“Nivolumab plus ipilimumab after sorafenib in patients with advanced HCC
5-year results of CheckMate 040
Annals of Oncology

Nivolumab 1 mg/kg plus ipilimumab 3 mg/kg Q3W (four doses), followed by nivolumab 240 mg Q2W

  • ORR: 34%
  • mDOR: 51.2 mo
  • mOS: 22.2 mo
  • 60-month OS rate: 29%″

Erman Akkus

Read the article.
Source: Erman Akkus/X
.

5-year results advanced HCC Annals of Oncology cancer cancer therapy cancer treatment CheckMate 040 clinical trial Erman Akkus Healthcare Research hepatocellular carcinoma immunotherapy ipilimumab mDoR median duration of response median overall survival mOS nivolumab objective response rate OncoDaily Oncology oncology research ORR Research sorafenib survival rates